Bris­tol My­ers buys in­to Reper­toire's au­toim­mune vac­cines, giv­ing new life to Flag­ship start­up

Flag­ship-in­cu­bat­ed Reper­toire Im­mune Med­i­cines has lined up an au­toim­mune dis­ease pact with Bris­tol My­ers Squibb, mark­ing the first ma­jor up­date from the well-fund­ed start­up in about two years.

Bris­tol My­ers will dish out $65 mil­lion up­front to the Cam­bridge, MA-based start­up as they look to cre­ate so-called “to­ler­iz­ing vac­cines” for up to three undis­closed au­toim­mune dis­eases. The deal could bal­loon to $1.8 bil­lion if all mile­stones are met, the com­pa­nies said Mon­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER